JP4763282B2 - 骨発生の調節方法 - Google Patents

骨発生の調節方法 Download PDF

Info

Publication number
JP4763282B2
JP4763282B2 JP2004510828A JP2004510828A JP4763282B2 JP 4763282 B2 JP4763282 B2 JP 4763282B2 JP 2004510828 A JP2004510828 A JP 2004510828A JP 2004510828 A JP2004510828 A JP 2004510828A JP 4763282 B2 JP4763282 B2 JP 4763282B2
Authority
JP
Japan
Prior art keywords
bone
receptor
cells
cd200r
development
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2004510828A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006501167A (ja
JP2006501167A5 (https=
Inventor
レジナルド エム． ゴルツィンスキー
Original Assignee
トリリウム セラピューティクス インコーポレーティッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by トリリウム セラピューティクス インコーポレーティッド filed Critical トリリウム セラピューティクス インコーポレーティッド
Publication of JP2006501167A publication Critical patent/JP2006501167A/ja
Publication of JP2006501167A5 publication Critical patent/JP2006501167A5/ja
Application granted granted Critical
Publication of JP4763282B2 publication Critical patent/JP4763282B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2004510828A 2002-06-07 2003-06-06 骨発生の調節方法 Expired - Fee Related JP4763282B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38656402P 2002-06-07 2002-06-07
US60/386,564 2002-06-07
PCT/CA2003/000823 WO2003103709A2 (en) 2002-06-07 2003-06-06 Modulation of bone development

Related Child Applications (2)

Application Number Title Priority Date Filing Date
JP2010006754A Division JP2010155843A (ja) 2002-06-07 2010-01-15 骨発生の調節方法
JP2010175910A Division JP2010285448A (ja) 2002-06-07 2010-08-05 骨発生の調節方法

Publications (3)

Publication Number Publication Date
JP2006501167A JP2006501167A (ja) 2006-01-12
JP2006501167A5 JP2006501167A5 (https=) 2010-10-28
JP4763282B2 true JP4763282B2 (ja) 2011-08-31

Family

ID=29736181

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004510828A Expired - Fee Related JP4763282B2 (ja) 2002-06-07 2003-06-06 骨発生の調節方法
JP2010006754A Pending JP2010155843A (ja) 2002-06-07 2010-01-15 骨発生の調節方法
JP2010175910A Withdrawn JP2010285448A (ja) 2002-06-07 2010-08-05 骨発生の調節方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010006754A Pending JP2010155843A (ja) 2002-06-07 2010-01-15 骨発生の調節方法
JP2010175910A Withdrawn JP2010285448A (ja) 2002-06-07 2010-08-05 骨発生の調節方法

Country Status (6)

Country Link
US (3) US20050287603A1 (https=)
EP (1) EP1532176A2 (https=)
JP (3) JP4763282B2 (https=)
AU (2) AU2003233721B2 (https=)
CA (1) CA2487428A1 (https=)
WO (1) WO2003103709A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2462883A1 (en) * 2001-10-12 2003-04-17 Schering Corporation Use of bispecific antibodies to regulate immune responses
MXPA05006978A (es) * 2002-12-27 2005-08-16 Schering Corp Metodos para inducir y mantener la tolerancia inmune.
AU2008206502A1 (en) * 2007-01-11 2008-07-24 Boehringer Ingelheim International Gmbh CD200 and its receptor, CD200R, modulate bone mass via the differentiation of osteoclasts
US8647871B2 (en) 2007-03-30 2014-02-11 Escape Therapeutics, Inc. Endogenous expression of HLA-G and/or HLA-E by mesenchymal cells
WO2014113704A2 (en) 2013-01-18 2014-07-24 Escape Therapeutics, Inc. Enhanced differentiation of mesenchymal stem cells

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5641747A (en) * 1994-07-25 1997-06-24 Temple University-Of The Commonwealth System Of Higher Education Treatment of osteopetrotic diseases
US20020192215A1 (en) * 1999-04-13 2002-12-19 Schering Corporation, A New Jersey Corporation Novel uses of mammalian OX2 protein and related reagents
DE60034871T2 (de) * 1999-09-03 2008-01-17 Amgen Inc., Thousand Oaks Verfahren und zusammensetzungen zur prevention oder behandlung von krebs und von krebs assoziertem knochenverlust
KR20040028601A (ko) * 2000-09-05 2004-04-03 더 락커펠러 유니버시티 파골세포-관련 수용체
DK1482973T3 (da) * 2002-03-15 2009-12-07 Schering Corp Fremgangsmåde til modulering af CD200-receptorer

Also Published As

Publication number Publication date
JP2006501167A (ja) 2006-01-12
US20090214573A1 (en) 2009-08-27
AU2009217461A1 (en) 2009-10-15
CA2487428A1 (en) 2003-12-18
JP2010285448A (ja) 2010-12-24
WO2003103709A3 (en) 2004-04-08
AU2003233721B2 (en) 2009-07-02
US20050287603A1 (en) 2005-12-29
WO2003103709A2 (en) 2003-12-18
US20110189201A1 (en) 2011-08-04
EP1532176A2 (en) 2005-05-25
AU2003233721A1 (en) 2003-12-22
JP2010155843A (ja) 2010-07-15

Similar Documents

Publication Publication Date Title
Sunyer et al. Estrogen’s bone-protective effects may involve differential IL-1 receptor regulation in human osteoclast-like cells
KR102003571B1 (ko) 골형성 촉진제
TWI636994B (zh) Ｄｋｋ１抗體及使用方法
US20030215450A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20040171117A1 (en) Anti-RANK ligand monoclonal antibodies useful in treatment of RANK ligand mediated disorders
WO2002043759A2 (en) Method and composition for modulating bone growth
TW200539890A (en) Methods of modulating immune responses by modulating tim-1, tim-2 and tim-4 function
US6998123B1 (en) Osteoporosis treatment with anti-IL-11 antibody
CA2919477A1 (en) Compositions and methods for modulating thermogenesis using pth-related and egf-related molecules
US20110189201A1 (en) Modulation of bone development
CN105555291B (zh) 用于治疗雄性不育症的抗体、化合物及其衍生物
US7357929B2 (en) Placental growth factor as a target for the treatment of osteoporosis
JP2006501167A5 (https=)
CA2538229A1 (en) Treatment of rheumatoid arthritis with cd99 antagonists
US20040213788A1 (en) Anti-rank ligand monoclonal antibodies useful in treatment of rank ligand mediated disorders
US20090258021A1 (en) Genes associated with mechanical stress, expression products therefrom, and uses thereof
JP2005515752A6 (ja) Ｒａｎｋリガンド媒介性障害の治療において有用な抗ｒａｎｋリガンドモノクローナル抗体
JP2005515752A (ja) Ｒａｎｋリガンド媒介性障害の治療において有用な抗ｒａｎｋリガンドモノクローナル抗体
Lecanda et al. Impaired intramembranous bone formation in connexin43 null mice
EP1819346A2 (en) Oxytocin receptor antagonists and their use for the treatment of pulmonary related diseases
EP1521591B1 (fr) UTILISATION D'UN ANTICORPS ANTI-PTHrP(34-53) COMME ANTAGONISTE DE LA PTHrP POUR TRAITER LE CARCINOME A CELLULES RENALES
JP4227778B2 (ja) アネキシン５の生理活性抑制物質
US20040005997A1 (en) Methods for identifying compounds for regulating muscle mass of function using amylin receptors

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060518

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090715

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20091009

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20091019

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100115

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100405

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100805

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100805

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20100805

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20100910

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101022

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20101101

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110427

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20110530

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20110609

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20140617

Year of fee payment: 3

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees